Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments

Maria Geis; Boris Nowotny; Marc-Dominic Bohn; Dina Kouhestani; Hermann Einsele; Thomas Bumm; Gernot Stuhler

doi:10.1038/s42003-020-01558-0

Communications Biology (Jan 2021)

Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments

Maria Geis,
Boris Nowotny,
Marc-Dominic Bohn,
Dina Kouhestani,
Hermann Einsele,
Thomas Bumm,
Gernot Stuhler

Affiliations

Maria Geis: Department of Internal Medicine II, Hematology and Oncology, University Clinic Würzburg
Boris Nowotny: Department of Internal Medicine II, Hematology and Oncology, University Clinic Würzburg
Marc-Dominic Bohn: Department of Internal Medicine II, Hematology and Oncology, University Clinic Würzburg
Dina Kouhestani: Department of Internal Medicine II, Hematology and Oncology, University Clinic Würzburg
Hermann Einsele: Department of Internal Medicine II, Hematology and Oncology, University Clinic Würzburg
Thomas Bumm: Department of Internal Medicine II, Hematology and Oncology, University Clinic Würzburg
Gernot Stuhler: Department of Internal Medicine II, Hematology and Oncology, University Clinic Würzburg

DOI: https://doi.org/10.1038/s42003-020-01558-0
Journal volume & issue: Vol. 4, no. 1
pp. 1 – 6

Abstract

Read online

Geis et al. investigate the potential application of hemibodies, a pair of complementary antibody fragments that redirect T cells against cancer-defining antigen combinations, such as CD38 and SLAMF7, to target multiple myeloma. Their study provides evidence that hemibodies can be developed for effective immunotherapy against multiple myeloma.

Published in Communications Biology

ISSN: 2399-3642 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General)
Website: https://www.nature.com/commsbio/

About the journal